Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M
Cancer Cell. 2010 18 (6): 683-95

PMID: 21156289 · PMCID: PMC3026446 · DOI:10.1016/j.ccr.2010.11.023

MeSH Terms (13)

Cell Line, Tumor Drug Resistance, Neoplasm Humans MAP Kinase Signaling System Melanoma Mitogen-Activated Protein Kinase Kinases Phosphatidylinositol 3-Kinases Phosphoinositide-3 Kinase Inhibitors Phosphorylation Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins c-akt raf Kinases Receptor, IGF Type 1

Connections (1)

This publication is referenced by other Labnodes entities: